產(chǎn)品名稱：AMO-1人漿細(xì)胞骨髓瘤細(xì)胞,、AMO-1人漿細(xì)胞骨髓瘤細(xì)胞,、AMO-1人漿細(xì)胞骨髓瘤細(xì)胞、AMO-1人漿細(xì)胞骨髓瘤細(xì)胞,；

the 20th century, scientists have tried to stimulate the anti-tumour activities of the immune system to fight against cancer. However, the scientific effort devoted on the development of cancer immunotherapy has not been translated into the expected clinical success. On the contrary, classical anti-neoplastic treatments such as surgery, radiotherapy and chemotherapy are the first line of treatment. Nevertheless, there is compelling